Navigation Links
Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting
Date:11/14/2011

tion of heart failure hospitalization events.  Mesoblast expects that these outcomes will be central to the primary endpoint of a Revascor™ Phase 3 trial for product regulatory approval by the United States Food and Drug Administration (FDA).

The randomized, placebo-controlled 60-patient Phase 2 trial compared the safety and efficacy of three doses of Revascor™ on top of maximal approved therapies versus maximal therapies alone in patients with moderate-to-severe congestive heart failure (CHF) defined by New York Heart Association (NYHA) class II or III status and ejection fraction below 40%.  The trial enrolled both ischemic and non-ischemic heart failure patients.  Heart failure patients with this degree of severity are known to have a high cardiac mortality over a 12-24 month period despite being on maximal approved drug and device therapies.

Treatment with MPCs was well-tolerated, with 13% of patients developing transient or persistent anti-donor antibodies which were without clinical consequence. Over a 22-month mean follow-up period, only 1/45 (2%) patients who received a single injection of Revascor™ died of cardiac causes compared with 3/15 (20%) controls (p=0.02).  In addition, MPC treatment significantly delayed the time to a first Major Adverse Cardiac Event, MACE, a composite of cardiac death, heart attack or revascularization procedures (p=0.036), and reduced the overall risk for MACE by 78% (p=0.011).

Over a mean follow-up of 18 months, 0/15 patients who received the highest dose of MPC (150M) had been hospitalized for heart failure or had died.  In contrast, 3/15 (20%) controls and 6/30 (20%) patients who received low (25M) or mid (75M) doses of MPC had either been hospitalized with heart failure or had died. This clinical improvement associated with the 150M dose was accompanied by evidence of cardiac remodelling (reduction in left ventricular end systolic volumes compared with controls
'/>"/>

SOURCE Mesoblast
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Positive Data for Nektars New Mu-Opioid Analgesic Molecule to Treat Acute Pain Highlighted at Neuroscience 2011
2. Ampio Pharmaceuticals Announces Positive Results on Ampion™ Trial for Relief of Nasal Inflammation
3. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
4. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
5. NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinsons Disease
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
9. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
10. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
11. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013 A decade-long ... in Helmholtz Zentrum München, Germany , ... autoantibodies and the risk of developing type 1 diabetes ... preventions for the disease. The study, "Seroconversion to Multiple ... Children," was published today in The Journal of ...
(Date:6/19/2013)... --  Voices Against Brain Cancer (VABC), a not-for-profit ... today announced that it has awarded Tocagen Inc. ( ... of Toca 511 & Toca FC in patients diagnosed ... 3 or Grade 4).  Tocagen is a privately held ... an initial focus on brain cancer. "Every ...
(Date:6/19/2013)... , June 19, 2013 Amerivet ... company servicing all branches of government from Federal ... have expanded their facilities to include complex metal ... and fabricated some very complex aluminum parts for ... to expand our capabilities to service government contracts," ...
Breaking Medicine Technology:New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 2New Data on Islet Autoantibodies in Young Children Defines Early Type 1 Diabetes Development 3Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Amerivet Solutions Expands to Manufacture Complex Metal Designs 2
... Oct. 6, 2011 Kimberly-Clark Professional*, a global ... cleanrooms, and TerraCycle, a leading "upcycling" company, have ... cleanroom garments, including coveralls, hoods, boot covers, hair ... collaboration, Kimberly-Clark Professional will become among the first ...
... LLC ("ClearChoice"), a market leading developer and manager of ... same-day dental implant care, today announced a growth ... consumer-focused private equity firm. The investment will ... its expansion plan to double the number of ClearChoice ...
Cached Medicine Technology:Kimberly-Clark Professional* Partners With TerraCycle to Help Customers Recycle Cleanroom Garments 2Kimberly-Clark Professional* Partners With TerraCycle to Help Customers Recycle Cleanroom Garments 3ClearChoice Receives Investment From Leading Consumer Private Equity Firm Catterton Partners 2ClearChoice Receives Investment From Leading Consumer Private Equity Firm Catterton Partners 3ClearChoice Receives Investment From Leading Consumer Private Equity Firm Catterton Partners 4
(Date:6/19/2013)... DiscountFurnaceFilter.com, the number one solution for homeowner’s ... Compressor Saver kit at an exceptional price. The 5-2-1 Compressor ... air conditioning unit during start up, saving wear and tear ... unit burn out. , The 5-2-1 Compressor Saver ... uses less power to start and drastically reduces the rush ...
(Date:6/19/2013)... Guests at the Residence Inn Scottsdale Paradise Valley ... go to bed or rise early thanks to a new ... , Crafty travelers will have a little extra change in ... Paradise Valley hotel’s Book Early and Save Up to ... notice, guests can enjoy the year-round Scottsdale sunshine in deluxe ...
(Date:6/19/2013)... Many trying-to-conceive couples seek medical intervention ... to a recent study published in ... of this research confirm what Fairhaven Health has ... that trying-to-conceive women would benefit from tracking ovulation, ... Fairhaven Health is a leading provider of ovulation ...
(Date:6/19/2013)... disease Amyotrophic lateral sclerosis (ALS), also known as Lou ... can be classified into four distinct stages, report pathologists ... of Pennsylvania in the Annals of Neurology . ... tissues shows, for the first time, how the fatal ... the central nervous system to other regions of brain ...
(Date:6/19/2013)... Elsevier, a world-leading provider of scientific, technical ... the publication of the National Osteoporosis Guideline Group ... osteoporosis in postmenopausal women and older men in ... 2009 in Maturitas , the original guidelines ... timely with an additional focus on the management ...
Breaking Medicine News(10 mins):Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 2Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 3Health News:Plan Ahead and Save Big With New Deal From Residence Inn Scottsdale Paradise Valley 4Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2
... March 13, 2012Imagine that you have asthma, and rather than give ... have an attack, your doctor invites you to help write them? ... managing their health care, and would that ultimately make them happier ... Samir Gupta, a respirologist at St. Michael,s Hospital. His research ...
... each year in the United States because of mistakes made ... before a stoplight intersection where the traffic light turns yellow ... ahead. New research at Oregon State University will help ... then use than information, along with advanced technology that can ...
... topical gel now available by prescription significantly decreases the amount ... that is a common precursor to skin cancer, according to ... of Medicine. The gel, called ingenol mebutate, is applied ... quicker and even more effective as current therapies require weeks ...
... WEDNESDAY, March 14 (HealthDay News) -- A newly approved gel ... is a common precursor to squamous cell skin cancer, a ... even months to treat the condition, but the new product ... matter of days, according to the report in the March ...
... HealthDay Reporter , WEDNESDAY, March 14 (HealthDay News) ... beat back a genetic predisposition to be overweight, compared to ... research suggests. The findings don,t prove that the exercise ... possible that something else could explain why those who walked ...
... appetite can be a fleeting queasiness or continue to the ... is going on inside the head. ,New findings are emerging ... of appetite, and the systems in place to avoid starvation. ... brain circuit that mediates the loss of appetite in mice. ...
Cached Medicine News:Health News:St. Michael's doctor uses wiki to empower patients and help them to develop asthma action plans 2Health News:The 'twilight zone' of traffic costs lives at stoplight intersections 2Health News:New drug now available for actinic keratosis 2Health News:New Gel Treats Precancerous Skin Condition in Days: Study 2Health News:Brisk Daily Walk Could Counter 'Obesity Genes' 2Health News:Loss of appetite deciphered in brain cell circuit 2Health News:Loss of appetite deciphered in brain cell circuit 3
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
... HEp-2 cell line that has been genetically ... autoantibodies, without affecting the other ANA patterns ... worldwide on the HEp-2000 ANA substrate, which ... used in place of standard HEp-2 cells ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
Medicine Products: